Corruption, Crime & ComplianceBy Michael VolkovAugust 4, 2013The headlines get worse and worse. More companies under investigation. More individuals detained and under investigation. The shockwave in the pharmaceutical and medical device industries is palpable. It is all understandable. The message from the Chinese is two-fold – they are going to enforce China’s bribery laws, especially in those markets that have a direct and immediate nexus to China’s consumers… There are three types of bribery: [1] commercial bribery of business staff of a company; [2] official bribery of state functionaries or government organs; and [3] foreign bribery of any foreign public official or of an international public organization. The maximum penalties for bribery violations vary but the official bribery offense is punishable by death; the other two offenses, commercial and foreign bribery are punishable up to life imprisonment.
It would be a mistake for any company doing business in China to watch the unfolding investigation of the pharmaceutical and medical device companies and breathe a sigh of relief that it did not stretch to their industry. While healthcare is a significant consumer market in China, it does not take much of logical leap to start focusing on other consumer goods, including telecommunications, high-tech, real estate, consumer durables, automobiles and other industries which are high-risk in China. All of these industries produce goods and services which are important to China’s consuming class. It does not take much to stretch almost every industry under the scrutiny of China’s law enforcement for bribery enforcement. China recognizes the impact that the GSK investigation is having and will quickly realize the benefits of an active enforcement program which will generate revenue for its government, send a strong deterrence message to domestic and foreign actors, and improve China’s overall anti-corruption standing in the world.
China’s entry into the global anti-corruption enforcement arena is the single most important anti-corruption development for the year. Do not underestimate the implications of China’s rise from the ashes and its willingness to subject foreign national companies and individuals to bribery prosecutions. Global companies which have entered China have a new and significant risk – they are and will be subject to prosecution under the Chinese penal system. For many ex pats who are considering working in China, this may cause them to reconsider whether or not they are willing to enter the market for fear of being caught up in the Chinese judicial system which is not known for protecting individual due process rights…
Time will tell how significant China’s enforcement efforts will become. For now, the drug and device industry has to redouble their compliance efforts, investigate their operations, and take affirmative steps to improve their programs before the Chinese knock on their door. For companies in other industries, now is not the time to be penny wise and pound foolish – they should begin a re-examination and improvement of their compliance programs.hat tip to Pharmagossip
Unlike in the US, the Chinese like to make object lessons of those caught in this kind of corruption.
Not too long ago, the Chinese government hanged a food and drug bureaucrat for taking bribes http://www.chinadaily.com.cn/china/2007-07/10/content_5424937.htm
One can only hope this might apply to those involved in GSK’s schemes there.
Also, Altostrata, entire villages have killed particularly brutal and exploitative managers. They’re a long way from having strong unions, but it’s starting to look a little hopeful that the party/government is starting to take the health and well-being of its citizenry more seriously and starting to regulate businesses more.
In China, the health problems from pollution alone are staggering. Adding corrupt & money-grubbing westerners peddling drugs that don’t sell themselves just adds misery.
I confess, I want to see high-ranking CEOs in Glaxo burned so bad that they get very shy, quiet, and thoughtful.
GSK reminds me of BP in their PR handling of this mess.
Reposting a great article that gives great insights into the Big Pharma/government predation on the most vulnerable in society:
http://healthimpactnews.com/2013/genetic-research-lacks-science-political-social-control-is-genetics-agenda/
I am curious about your statement that patients are requesting medications since I haven’t found that to the be true for myself or any of my friends and co-workers.
In my case, working in a hospital as a pharmacy technician for several years, I learned to weigh the benefits vs the risks of a medication always. And, although I am not opposed to trying one, I will work to get off of it as quickly as possible even if it does alleviate a symptom(s).
For my friends and co-workers, what I have seen them do is to follow whatever “the authority” tells them to do, medication or otherwise (short on otherwise). However, they don’t seem to be real happy to be taking medications; it is just acquiescence.
I can only hope physicians are able to offer better options in the future than what they have been giving us. It scares me that there are a lot of me-too medications and therapies and very little new research on better alternatives. It doesn’t give a patient a whole lot of choices.
“I am curious about your statement that patients are requesting medications since I haven’t found that to the be true for myself or any of my friends and co-workers.”
Arby
The “system” dosn’t seem to lend itself to people getting better or finding alternatives to the Rx norms:
http://thelastpsychiatrist.com/2013/04/the_terrible_awful_truth_about_5.html
“The Terrible, Awful Truth About SSDI”